Figures
Abstract
Background
Hand-foot syndrome (HFS) is a relatively frequent dermatologic toxic reaction to certain anti-cancer chemotherapies. The syndrome can evolve into a distressing condition that limits function and affects quality of life. Pyridoxine (vitamin B6) has been used empirically for the prevention of HFS caused by anti-cancer therapy. However, evidence of its efficacy remains controversial.
Methodology//Principal Findings
Systematic literature searches were conducted on the Cochrane Library, PUBMED, EMBASE, LILACS, CBM, CNKI, VIP, WANFANG and the U.S. ClinicalTrials.gov website. We included all related randomized controlled trials (RCTs) irrespective of language. Reviewers from different professions independently assessed all potential studies and extracted data. Subgroup analysis was planned according to dose of pyridoxine. 5 RCTs involving 607 patients were contributed to the meta-analysis. No significant differences were found between patients receiving pyridoxine and placebo for prevention of incidence of HFS and grade 2 or worse HFS (relative risk (RR) 0.96, 95%confidence interval (CI) 0.86–1.06; RR0.95, 95%CI 0.73–1.24, respectively). Similarly, no significant improvement in quality of life was detected among patients. However, significant difference was found for prevention of grade 2 or worse HFS with pyridoxine 400 mg daily compared to 200 mg (RR0.55, 95%CI 0.33–0.92).
Conclusions/Significance
There is inadequate evidence to make any recommendation about using pyridoxine for prevention of HFS caused by chemotherapy. However, pyridoxine 400 mg may have some efficacy. Further studies of large sample sizes are needed to evaluate the efficacy and safety of pyridoxine, especially at high dose, in comparison with placebo.
Citation: Chen M, Zhang L, Wang Q, Shen J (2013) Pyridoxine for Prevention of Hand-Foot Syndrome Caused by Chemotherapy: A Systematic Review. PLoS ONE 8(8): e72245. https://doi.org/10.1371/journal.pone.0072245
Editor: William B. Coleman, University of North Carolina School of Medicine, United States of America
Received: April 5, 2013; Accepted: July 5, 2013; Published: August 20, 2013
Copyright: © 2013 Chen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing interests: The authors have declared that no competing interests exist.
Introduction
Hand-foot syndrome (HFS), also known as palmar-plantar erythrodysesthesia (PPE), palmar-plantar erythema, acral erythema and Burgdorf’s reaction, is a relatively frequent dermatologic toxic reaction to certain anti-cancer chemotherapies [1]. HFS has been reported in 6% to 42% of patients being treated with cancer chemotherapeutic agents, such as 5-fluorouracil (5-FU), doxorubicin, cytarabine, cyclophosphamide, vinorelbine, docetaxel or multikinase inhibitors sorafenib and sunitinib [2], [3].
The major clinical symptoms are typically described as a dermatologic reaction including erythema, swelling, twinge in the palms and soles [4]. The syndrome is usually mild, but can evolve into a distressing condition that limits function and affects quality of life (QoL). Although it is not a life threatening toxicity, HFS can be quite serious, resulting in dose reduction and shortened cancer treatment duration or intensity [5]. HFS toxicity is usually collected and scored according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE) by investigators and clinical research coordinators. In NCI-CTCAE version3.0, Grade 1 HFS is characterized by minimal skin changes or dermatitis without pain; grade 2 is characterized by skin changes or pain, but not interfering with function and grade 3 is characterized by ulcerative dermatitis or skin changes with pain interfering with function [6].
The pathogenesis of HFS is unclear to date [4]. Numerous approaches have been employed in attempts to prevent and/or reduce the incidence of HFS. Drug-related therapies include topical emollients and creams, systemic and topical corticosteroids, pyridoxine (vitamin B6), nicotine patch, vitamin E and COX-2 inhibitors [7]. As a relatively nontoxic and inexpensive treatment, pyridoxine has been used empirically for the prevention of HFS caused by antineoplastic chemotherapies [8], [9].
In recent years, many institutions such as the UK Addenbrooke's Hospital, the USA Thomas Hospital, the Korea University of Ulsan College of Medicine, the Thailand Chulalongkorn University, the China Luoyang Dongfang Hospital and the Singapore National Cancer Centre are ongoing or have completed randomized controlled trials to detect how well pyridoxine works in patients with chemotherapy [10], [11], [12], [13], [14], [15]. However, evidence of its efficacy remains controversial. Therefore, we performed a systematic review to evaluate the efficacy of pyridoxine which was administered for prevention or treatment of HFS in anti-cancer therapy.
Methods
Ethics Statement
The study was approved by the medical ethics committee of west china second university hospital.
Searching
We searched Cochrane Central Register of Controlled Trials (CENTRAL) published in Cochrane Library (2013, Issue 1), PUBMED, EMBASE using the search strategy detailed in table S1; we searched Chinese Biomedical Literature Database (CBM) and Chinese National Knowledge Infrastructure (CNKI); VIP Database for Chinese Technical Periodicals (VIP) and WANFANG for literatures published in Chinese. We also searched LILACS and the U.S. ClinicalTrials.gov website with the search term pyridoxin*, vitamin B6, hand foot syndrom* and palmar-plantar erythrodysesthesia. The references of all retrieved articles were scanned for additional relevant citations. We searched all databases from their earliest records to February 2013.
Eligibility Criteria
Randomized controlled trials published in full text or abstract only were both included, and there was no restriction on publication language. Eligibility criteria included adult patients older than 18 years receiving anti-cancer chemotherapies; Eastern Cooperative Oncology Group performance status 0–2; life expectancy more than 12 weeks and no contraindication to chemotherapy (i.e., adequate bone marrow function and normal renal and liver function). Exclusion criteria included previous treatment for HFS; hypersensitivity to pyridoxine; pregnancy or lactation. The intervention was pyridoxine (vitamin B6) regardless of the dose and duration, compared with placebo or no treatment. Studies that enrolled combination of drug use for HFS were also excluded.
Study Selection and Management
Reviewers from different professions independently assessed all potential studies and extracted data. Two authors (MC and QW) independently screened the title, abstract and key words of all studies identified by the search strategy and obtained the full articles for all potential relevant trials. Three authors(MC, QW and JTS)independently assessed the full text and extracted data using a data extraction form. Disagreement was resolved by discussion or consulting with the corresponding author (LLZ).
For dichotomous outcomes, we extracted the number of participants experiencing the event and the total number of participants evaluated for that outcome. For continuous outcomes, we extracted the mean, standard deviation (SD) or any data which could be used to derive the SD, and the total number of participants evaluated for that outcome [16]. Subgroup analysis was planned according to dose of pyridoxine.
Risk of Bias Assessment
Three authors(MC, QW and JTS) independently assessed the risk of bias using a standard form. We contacted the authors by phone or email if important information was unclear. We used the domain-based evaluation recommended by the Cochrane Handbook (Higgins 2011) to address six specific domains: sequence generation, allocation sequence concealment, blinding, incomplete outcome data, selective outcome reporting and other potential sources of bias [16].
Statistical Synthesis
As a measure of effectiveness, risk ratio (RR) with 95% confidence interval (CI) was calculated for the meta-analysis. We determined the presence of heterogeneity using I2 statistic and used the fixed-effect model to combine trials in the absence of substantial heterogeneity (I2<50%). By contrast, random-effect model was used when heterogeneity was significant (I2≥50%) and could not be explained by subgroup analysis, clinical or methodological features of the trials. Meta-analysis was performed using Review Manager Version5.1.0 software [17].
Results
Study Selection
Figure 1 showed the literature selection process. Based on the search strategy we identified 270 articles, of which 259 were excluded by the reviewers after reading the titles and abstracts. 11 relevant full articles were read and only 5 studies were included eventually [10], [11], [12], [13], [14].
This PRISMA 2009 flow diagram illustrates the results of search and the process of screening and selecting studies for inclusion, and the reasons for exclusions in this review.
Characteristics of Included Studies
Table 1 provided details for each trial. All studies described their hypothesis/objective and main findings clearly. 612 patients were included and the mean age was 62.1 years (range from 20–87). A wide range of cancer types including colorectal, breast, ovarian, stomach, biliary tract, endometrial, duodenum was represented, with colorectal the most common (350 patients). The capecitabine dose was initiated at 2000–2500 mg/m2 orally per day for alone or combined treatment, for 2 weeks followed by 7 days rest. The Pegylated Liposomal Doxorubicin dose was 40 mg/m2 intravenously every 4 weeks for single-agent therapy. The pyridoxine was prescribed orally commencing the same day that chemotherapy was initiated. Treatment continued until disease progression, toxicity or patient preference. 5 patients were excluded because of reactions to chemotherapy during the first course. The remaining 607 patients were contributed to the meta-analysis.
Risk of Bias Assessment in Included Studies
Figure 2 provided methodological details for each trial. None of the studies provided specific random sequence generation although they described randomized design. All studies had low risk bias in selective outcome reporting and other potential issues. However, one trial [14] had high risk bias in allocation concealment and blinding which was implemented by sensitivity analysis.
This plot is created by the software of RevMan 5.1.0. It illustrates the quality of included studies with each of the judgement (‘low risk’, ‘high risk’ or ‘unclear risk’ of bias). All studies had low risk bias in selective reporting and other issues, and unclear risk in random sequence generation. One study (Fang 2010) had high risk bias in allocation concealment and blinding.
Incidence of HFS
Four trials [10], [11], [12], [14] reported oral pyridoxine versus placebo in the incidence of HFS. We did not find any statistically significant difference in the incidence of HFS among patients receiving placebo compared to oral 150 mg daily of pyridoxine (relative risk (RR) 0.96; 95%confidence interval (CI) 0.67–1.39; n = 106) and oral pyridoxine 200 mg (RR0.96; 95%CI 0.86–1.06; n = 389) and oral pyridoxine 300 mg (RR0.92; 95%CI 0.57–1.50; n = 56). Totally, there were no statistically significant differences in the risk of HFS among patients receiving placebo compared to pyridoxine (RR0.96; 95%CI 0.86–1.06; n = 551) (Fig.3).
This forest plot is created by the software of RevMan 5.1.0. Horizontal lines indicate 95% CIs. Solid boxes indicate the response rate in each study. Test of heterogeneity (I2 = 0%) indicates the absence of substantial heterogeneity. The bottom of diamond indicates the pooled response rate (RR0.96, P = 0.99).
Incidence of Grade 2 or Worse HFS
We planned subgroup analysis according to dose of pyridoxine.
Pyridoxine versus Placebo.
Four trials [10], [11], [12], [14] reported oral pyridoxine versus placebo in the incidence of grade 2 or worse HFS. We did not find any statistically significant difference among patients receiving placebo compared to oral 150 mg daily of pyridoxine(RR0.56; 95%CI 0.20–1.55; n = 106) and oral pyridoxine 200 mg (RR1.06; 95%CI 0.79–1.43; n = 389) and oral pyridoxine 300 mg (RR0.60; 95%CI 0.24–1.51; n = 56). Totally, there were no statistically significant differences in the risk of grade 2 or worse HFS among patients receiving placebo compared to pyridoxine(RR0.95; 95%CI 0.73–1.24; n = 551)(Fig.4).
This forest plot is created by the software of RevMan 5.1.0. Test of heterogeneity (I2 = 0%) indicates the absence of substantial heterogeneity. The bottom of diamond indicates the pooled response rate (RR0.95, P = 0.28).
Different Doses of Pyridoxine.
One trial [13] reported oral pyridoxine 400 mg versus 200 mg in the incidence of grade 2 or worse HFS. Pyridoxine 400 mg was more effective in the prevention of grade 2 and grade 3 HFS than pyridoxine 200 mg (RR 0.55; 95% CI 0.33–0.92; n = 56) (Fig.5).
This forest plot is created by the software of RevMan 5.1.0. The diamond indicates the response rate (RR0.55, P = 0.02).
Time to the Development of Grade 2 or Worse HFS
One trial [13] reported the median time to the development of grade 2 or worse HFS in pyridoxine 400 mg group (87 days) was slightly longer than 200 mg group (61 days). However, we did not find any statistically significant difference (P = 0.44).
Quality of Life
Two trials [10], [12] evaluated the QoL between the pyridoxine and placebo groups. There were no significant differences between the two groups in the QoL no matter in 106 patients treated with capecitabine using the European Organization for Research and Treatment of Cancer QLQ-C30 instrument or 34 patients treated with pegylated liposomal doxorubicin using FACT-General instrument. Both of the instruments were used to assess the impact of HFS on QoL.
Sensitivity Analysis
We performed sensitivity analysis after exclusion of one RCT with low quality. After exclusion of the trial evaluating the use of pyridoxine in the prevention of HFS and grade 2 or worse HFS, Meta-analysis showed that the differences were not significant (RR0.96, 95% CI0.86–1.07; RR0.99, 95% CI0.75–1.32; respectively) (Table 2).
Discussion
Pyridoxine has been used frequently for HFS associated with chemotherapy. However, the mechanism by which pyridoxine protects against HFS is still not fully understood. In the patient’s hand, punch biopsy results showed vacuolar degeneration of the basal layer of the epidermis with cellular enlargement, spongiosis, mild exocytosis of small lymphocytes, and marked hyperkeratosis [1]. According to the metabolism of pyridoxine, it could be converted into pyridoxal phosphate in red blood cells. And pyridoxal has been discovered as a potent antagonist of P2X purinergic receptor, which accelerates repair of the skin barrier and prevents epithelial hyperplasia [18].
Pyridoxine has been used successfully at dose of 50 to 800 mg/day for treating and preventing fluorouracil-, docetaxel-, etoposide-, doxorubicin- and sorafenib-related PPE [19], [20], [21], [22], [23], [24], [25], [26]. In a case report, pyridoxine 100 mg three times daily was used successfully to treat PLD-related HFS [27]. A small study in 25 metastatic colorectal cancer patients showed that prophylactic pyridoxine at 50 or 150 mg daily might be useful in delaying the onset of severe PPE from fluorouracil [20]. And a double-blind clinical trial using a canine model proved the efficacy of pyridoxine in delaying the onset and severity of PPE during doxorubicin containing pegylated liposome chemotherapy [28]. Although pyridoxine has been shown to be effective, a negative effect on response duration was reported when pyridoxine was given at 300 mg/m2 to prevent hexamethylmelamine-related neurotoxicity [29].
Based on the current evidence, this is the first systematic review of five randomized controlled studies that estimates the efficacy of pyridoxine for the prevention or treatment of HFS. Results revealed that there was inadequate evidence to support the use of pyridoxine in the prevention of HFS caused by chemotherapy. No statistically significant differences were found among patients receiving pyridoxine (150 mg, 200 mg, 300 mg) compared with placebo. Moreover, the two sensitivity analyses showed similar results. Although pyridoxine was not preventative at 150–300 mg daily, it might be beneficial at high dose. Chalermchai et al (2010) suggested that high dose of pyridoxine 400 mg was more effective than 200 mg in the protection for incidence of grade 2 or worse HFS. Nevertheless, it was noteworthy that when the endpoint was incidence of grade 3 HFS or the time to onset of grade 2 or worse HFS in this RCT, no statistically significant differences were found between 400 mg and 200 mg groups. Therefore, the study results might be limited by small sample size.
In this review, another observation showed that pyridoxine had no meaningful impact on the quality of life in patients with anti-cancer therapy. In addition, all the studies eligible failed to compare effectiveness in the time to development of HFS, chemotherapy drug dose modification, progression-free survival, incidence of adverse events excluding HFS among pyridoxine and control groups.
Our study has several limitations. First, information from primary studies was not sufficient to perform subgroup analysis by types of chemotherapy regimen. To our knowledge, the frequency of HFS in patients differs between various medical tumor therapies. It has been reported in 50–60% of patients being treated with capecitabine and 22–26% with doxorubicin [5]. Besides, this review only included randomized controlled trials in which adverse effects of pyridoxine were not assessed absolutely. All of these need improvement in future studies.
Conclusions
Based on the data from five randomized controlled trials, there is inadequate evidence to make any recommendation about using pyridoxine for prevention of HFS caused by chemotherapy. However, pyridoxine 400 mg may have some efficacy. Further studies of large sample sizes are needed to evaluate the efficacy and safety of pyridoxine, especially at high dose, in comparison with placebo.
HFS is a common health problem among patients with chemotherapy. And any treatment which might prove to be effective is worth investigation.
Supporting Information
Table S1.
Search strategy for PUBMED, CENTRAL and EMBASE.
https://doi.org/10.1371/journal.pone.0072245.s001
(DOC)
Table S2.
PRISMA checklist applied to this review.
https://doi.org/10.1371/journal.pone.0072245.s002
(DOC)
Author Contributions
Conceived and designed the experiments: MC LLZ QW. Performed the experiments: MC LLZ QW JTS. Analyzed the data: MC QW JTS. Contributed reagents/materials/analysis tools: LLZ JTS. Wrote the paper: MC LLZ QW.
References
- 1. Gressett SM, Stanford BL, Hardwicke F (2006) Management of hand-foot syndrome induced by capecitabine. Journal of Oncology Pharmacy Practice 12: 131–141.
- 2. Nagore E, Insa A, Sanmartín O (2000) Antineoplastic Therapy-Induced Palmar Plantar Erythrodysesthesia ('Hand-Foot') Syndrome: Incidence, Recognition and Management. American Journal of Clinical Dermatology 1: 225–234.
- 3. Lipworth AD, Robert C, Zhu AX (2009) Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology 77: 257–271.
- 4. von Moos R, Thuerlimann BJ, Aapro M, Rayson D, Harrold K, et al. (2008) Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts. Eur J Cancer 44: 781–790.
- 5. Degen A, Alter M, Schenck F, Satzger I, Völker B, et al. (2010) The hand-foot-syndrome associated with medical tumor therapy–classification and management. Journal der Deutschen Dermatologischen Gesellschaft 8: 652–661.
- 6. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, et al. (2003) CTCAE v3. 0: development of a comprehensive grading system for the adverse effects of cancer treatment. Seminars in radiation oncology13: 176–181.
- 7. Disel U, Gürkut Ö, Abali H, Kaleagasi H, Mertsoylu H, et al. (2010) Unilateral hand-foot syndrome: an extraordinary side effect of capecitabine. Cutaneous and Ocular Toxicology 29: 140–142.
- 8. Nagore Enguidanos E, Sanchez-Motilla JM, Insa Molla A, Febrer MI (1998) Palmar-plantar erythrodysaesthesia syndrome secondary to 5-fluorouracil therapy: Successful treatment with pyridoxine. Medicina Cutanea Ibero-Latino-Americana 26: 35–38.
- 9. Janusch M, Fischer M, Marsch W, Holzhausen H, Kegel T, et al. (2006) The hand-foot syndrome–a frequent secondary manifestation in antineoplastic chemotherapy. Eur J Dermatol 16: 494–499.
- 10. Corrie PG, Bulusu R, Wilson CB, Armstrong G, Bond S, et al. (2012) A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications. Br J Cancer 107: 585–587.
- 11. Kang YK, Lee SS, Yoon DH, Lee SY, Chun YJ, et al. (2010) Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study. Journal of clinical oncology 28: 3824–3829.
- 12. Gruenigen V, Frasure H, Fusco N, DeBernardo R, Eldermire E, et al. (2010) A double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gynecologic oncology patients. Cancer 116: 4735–4743.
- 13. Chalermchai T, Tantiphlachiva K, Suwanrusme H, Voravud N, Sriuranpong V (2010) Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia. Asia-Pacific Journal of Clinical Oncology 6: 155–160.
- 14. Fang XH, Wu Q, Han XM, Cao TH, Liu LJ, et al. (2010) High dose pyridoxine for the prevention of hand-foot syndrome caused by capecitabine. Oncology 30: 1081–1082.
- 15.
ClinicalTrials.gov website. Pyridoxine in Preventing Hand-Foot Syndrome Caused by Capecitabine in Patients With Cancer. Available: http://www.clinicaltrials.gov/ct2/show/NCT00486213?term=pyridoxine&rank=9. Accessed 2013 Feb 25.
- 16.
Higgins J, Green S (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available: http://handbook.cochrane.org. Accessed 2013 Mar 4.
- 17.
Collaboration RTC (2011) Review Manager (RevMan). 5.1. Copenhagen, The Nordic Cochrane Centre: The Cochrane Collaboration.
- 18. Denda M, Inoue K, Fuziwara S, Denda S (2002) P2X Purinergic Receptor Antagonist Accelerates Skin Barrier Repair and Prevents Epidermal Hyperplasia Induced by Skin Barrier Disruption. Journal of investigative dermatology 119: 1034–1040.
- 19. Banfield G, Crate I, Griffiths C (1995) Long-term sequelae of Palmar-Plantar erythrodysaesthesia syndrome secondary to 5-fluorouracil therapy. Journal of the Royal Society of Medicine 88: 356–357.
- 20. Fabian CJ, Molina R, Slavik M, Dahlberg S, Giri S, et al. (1990) Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Investigational New Drugs 8: 57–63.
- 21. Gordon KB, Tajuddin A, Guitart J, Kuzel TM, Eramo LR, et al. (1995) Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy. Cancer 75: 2169–2173.
- 22. Mortimer JE, Anderson I (1990) Weekly fluorouracil and high-dose leucovorin: efficacy and treatment of cutaneous toxicity. Cancer Chemotherapy and Pharmacology 26: 449–452.
- 23. Portal I, Cardenal F, Garcia-del-Muro X (1994) Etoposide-related acral erythema. Cancer Chemotherapy and Pharmacology 34: 181.
- 24. Vukelja SJ, Lombardo FA, James WD, Weiss RB (1989) Pyroxidine for the Palmar-Plantar Erythrodysesthesia Syndrome. Annals of Internal Medicine 111: 688–689.
- 25. Vukelja SJ, Baker WJ, Burris HA, Keeling JH, Von HD (1993) Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with taxotere. Journal of the National Cancer Institute 85: 1432–1433.
- 26. Azad NS, Aragon-Ching JB, Dahut WL, Gutierrez M, Figg WD, et al. (2009) Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clinical Cancer Research 15: 1411–1416.
- 27. Hau P, Fabel K, Baumgart U, Rümmele P, Grauer O, et al. (2004) Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer 100: 1199–1207.
- 28. Vail DM, Chun R, Thamm DH, Garrett LD, Cooley AJ, et al. (1998) Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model. Clin Cancer Res 4: 1567–1571.
- 29. Wiernik PH, Yeap B, Vogl SE, Kaplan BH, Comis RL, et al. (1992) Hexamethylmelamine and low or moderate dose cisplatin with or without pyridoxine for treatment of advanced ovarian carcinoma: a study of the Eastern Cooperative Oncology Group. Cancer Investigation 10: 1–9.